Table 1.
Phenotypic characterization of ADSCs-SVF after isolation and activation with PRP and photobiostimulation in all patients enrolled (n=14) in the study
| |
Differentiation markers |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients | CD29 | CD13 | CD73 | CD90 | CD105 | CD116 | CD44 | CD34 | CD31 | CD45 |
|
1 |
65.2 |
41.8 |
61.6 |
60.1 |
49.2 |
59.1 |
88.5 |
21.2 |
0.8 |
0.1 |
|
2 |
78.3 |
50.3 |
66.8 |
45.3 |
53.1 |
56.2 |
91.2 |
25.5 |
0.5 |
0.2 |
|
3 |
81.5 |
47.9 |
56.3 |
57.6 |
47.7 |
59.2 |
92.1 |
31.1 |
0.3 |
0 |
|
4 |
79.9 |
51.8 |
66.2 |
61.8 |
50.6 |
61.8 |
90.2 |
35.6 |
0 |
0.1 |
|
5 |
80.4 |
37.2 |
55.2 |
45.7 |
48.7 |
49.4 |
92.7 |
22.2 |
0.2 |
0.5 |
|
6 |
82.2 |
54.1 |
78.9 |
69.8 |
54.5 |
63.9 |
91.4 |
35.7 |
1 |
0 |
|
7 |
81.6 |
53.3 |
76.6 |
68.8 |
49.9 |
62.8 |
88.6 |
27.9 |
0.7 |
0 |
|
8 |
86.7 |
56.3 |
68.7 |
59.9 |
51.4 |
62.6 |
90.1 |
33.1 |
0.8 |
0.2 |
|
9 |
77.4 |
43.6 |
57.5 |
64.1 |
49.4 |
62.7 |
93.2 |
27.9 |
1.1 |
0.1 |
|
10 |
78.8 |
58.7 |
66.9 |
52.8 |
45.1 |
62.9 |
88.9 |
21.6 |
08 |
0.1 |
|
11 |
76.9 |
60.1 |
77.9 |
59.6 |
48.8 |
59.6 |
89.4 |
26.4 |
0.9 |
1 |
|
12 |
78.9 |
51.9 |
50.9 |
59.9 |
52.2 |
63.8 |
90.6 |
37.1 |
0.9 |
0.3 |
|
13 |
80.3 |
52.8 |
79.1 |
61.7 |
49.8 |
64.1 |
89.3 |
25.4 |
1 |
0.2 |
|
14 |
79.7 |
49.6 |
75.8 |
65.5 |
51.8 |
63.7 |
88.8 |
30.5 |
0.6 |
0 |
| Median % (range) | 79.1 |
54.2 |
67.7 |
59.3 |
50.1 |
60.8 |
90,3 |
28.8 |
0.7 |
0.2 |
| (65.2 – 86.7) | (37.2 – 67.1) | (55.2 – 79.1) | (45.3 – 69.4) | (48.7 – 58.2) | (49.4- 64.1) | (88.5 – 93.6) | (21.2 – 37.1) | (0–1.1) | (0.2-1) | |
Abbreviations: ADSCs-SVF Adipose derived stromal cells-stromal vascular fraction.